Every material Form 8-K Spyre Therapeutics, Inc. has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Spyre Therapeutics reported a third-quarter 2026 net loss of $96.1 million, up from $11.2 million a year earlier, as research and development expenses nearly doubled. The company also reported mixed trial results, with positive induction data for SPY003 in IBD but no plan to advance SPY072 in rheumatic diseases, and said its pro forma cash runway extends into the second half of 2029.
Net loss was $96.1 million for Q3 2026 versus $11.2 million for Q3 2025; net loss per common share was $(0.94) versus $(0.15).
R&D expenses rose to $89.2 million from $45.2 million, driven mainly by higher manufacturing costs and clinical trial expenses.
Prior-year other income included changes in the fair value of the CVR liability; Q3 2026 total other income was $9.6 million versus $45.7 million.
Pro forma cash, cash equivalents and marketable securities were $1,467.9 million as of September 30, 2026, including $378.0 million in net proceeds from an October 2026 public offering.
On October 5, 2026, Spyre Therapeutics agreed to sell 4,117,648 shares of common stock at $85.00 per share, with expected gross proceeds of about $350.0 million before underwriting discounts and offering expenses. The underwriters also received a 30-day option to buy up to 617,647 additional shares, and closing is expected on or about October 7, 2026. Because the offering adds new shares, existing shareholders' ownership will be diluted once it closes, and the proceeds are earmarked for pipeline programs in gastroenterology, rheumatology, dermatology, and SPY072 for hidradenitis suppurativa.
4,117,648 shares offered at $85.00 per share, with Jefferies LLC and other firms as representatives of the underwriters
Expected gross proceeds of about $350.0 million before underwriting discounts and estimated offering expenses
Underwriters hold a 30-day option to purchase up to 617,647 additional shares; closing expected on or about October 7, 2026
Proceeds to fund programs in Gastroenterology, Rheumatology and Dermatology, including late-stage development of SPY072 for hidradenitis suppurativa
Spyre Therapeutics reported 12-week Part A induction results from the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 antibody in development for moderately-to-severely active ulcerative colitis. SPY003 met its primary endpoint with a 10.0-point reduction in Robarts Histopathology Index score from baseline (p<0.0001), and the company reported no drug-related serious adverse events for the drug. For shareholders, the results complete proof-of-concept for all three monotherapy components of the company's IBD combinations, but the data come from a 44-subject open-label study and do not include financial results.
Primary endpoint: 10.0-point RHI reduction at Week 12 (p<0.0001) in 44 subjects receiving SPY003, with clinical remission at 20% and endoscopic improvement at 30%
Safety: 19 subjects (43%) had treatment-emergent adverse events; 3 serious adverse events were reported, all deemed not drug-related
Next readouts: SKYWAY sub-studies (SPY072) expected 4Q 2026; SKYLINE Part B topline induction data expected in 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Spyre Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →